Johnson & Johnson (JNJ) Stock Faces Margin Squeeze As Q2 Net Profitability Undercuts Bullish Narrative

Johnson & Johnson (JNJ) just posted Q2 2026 revenue of US$25.3 billion and basic EPS of US$2.27, with trailing 12 month EPS at US$8.70 and net income of US$21.0 billion framing the latest quarter against a much larger earnings base. Over recent quarters the company has seen revenue move from US$23.7 billion in Q2 2025 through a range of roughly US$24.0 billion to US$24.6 billion, while quarterly EPS has tracked between US$2.10 and US$2.30 outside of a one off spike in early 2025. This sets a clear context for how consistent its top and bottom line have been. For investors, the key takeaway this season is how those steady headline numbers translate into margins in light of a lower reported net margin over the past year and a large one off gain sitting in the trailing figures.

See our full analysis for Johnson & Johnson.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the main stories investors tell about Johnson & Johnson, and where the fresh results might push those narratives to adjust.

See what the community is saying about Johnson & Johnson

Margins Under Pressure at 21.5%

• Over the last 12 months, Johnson & Johnson converted US$97.9b of revenue into US$21.0b of net income, which works out to a 21.5% net margin compared with 25% a year earlier.
• Bears argue that margin pressure will persist as loss of exclusivity, tariffs of about US$500m in 2026 and restructuring weigh on profitability, and the current 21.5% margin ties into that view by:
  • Showing that profitability is already below the prior 25% level, which bearish analysts assume could shrink further toward 19.8% in their scenario.
  • Aligning with concerns that higher costs and pricing pressure in MedTech and Immunology could keep consolidated earnings from expanding as quickly as revenue.

For a closer look at how skeptics frame these margin risks against Johnson & Johnson's pipeline and capital plans, have a look at the 🐻 Johnson & Johnson Bear Case.

P/E Of 28.6x Versus Industry 15.2x

• Johnson & Johnson trades on a trailing P/E of 28.6x, compared with the US Pharmaceuticals industry average of 15.2x and a peer average of 28.2x, while a DCF fair value of US$377.51 sits above the current US$249.97 share price.
• What stands out for the bullish narrative is the tension between this higher P/E and the DCF fair value, because:
  • The shares are shown about 33.8% below the DCF fair value, while analysts also expect earnings to reach US$26.9b by around 2029 with margins rising from 21.8% to 23.1% in their consensus scenario.
  • At the same time, the current premium P/E means bulls are effectively arguing that Johnson & Johnson deserves to trade well above the industry because of its portfolio, pipeline and planned US$55b of investment in manufacturing, R&D and technology.

If you want to see how those growth expectations and valuation arguments come together in the bullish case, check out the 🐂 Johnson & Johnson Bull Case.

Steady EPS, But One Off Gain Matters

• Earnings per share over the last six quarters have mostly sat in a tight band around US$2.10 to US$2.30, yet the trailing 12 month EPS of US$8.70 and net income of US$21.0b are affected by a US$5.5b one off gain.
• Consensus narrative points to mid single digit revenue growth of about 6.6% a year and earnings growth of around 9.24% a year, and the one off gain matters for that view because:
  • It inflates recent profit relative to the underlying run rate suggested by quarterly net income figures near US$5.1b to US$5.5b, which investors need to keep in mind when comparing to forward earnings targets such as US$22.6b or US$26.9b by 2029.
  • It means some of the gap between the current US$249.97 share price and the DCF fair value or the 269.95 analyst target is being weighed against earnings that are not entirely from recurring operations.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Johnson & Johnson on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between concerns about margin risks and optimism around Johnson & Johnson's investment plans, this is a good moment to move from headlines to the underlying figures and judge the balance of risks and rewards for yourself by reviewing the 3 key rewards and 2 important warning signs.

See What Else Is Out There Beyond Johnson & Johnson

For all of Johnson & Johnson's consistency, the combination of margin pressure, one off gains and a premium P/E raises questions about how much safety and value you are really getting at the current price.

If that mix leaves you wanting a clearer balance between quality, valuation and downside protection, it is worth lining J&J up against other companies through the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com